J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
Betsy Goodfellow | February 12, 2024 | News story | Medical Communications | Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn (HDFN).
The drug is the only therapy currently in development for this indication, which is a rare condition that can occur when the blood types of a pregnant individual and the foetus are incompatible, leading to potentially life-threatening anaemia in the foetus or infant.
This designation follows data from the proof-of-concept phase 2 open-label UNITY clinical trial, which met its primary endpoint of the majority of pregnant patients receiving the drug achieving a live birth at or after a gestational age of 32 weeks without needing an intrauterine transfusion (IUT) throughout their pregnancy.
Severe or serious adverse events were generally low and remained consistent with events associated with pregnancy, HDFN and gestational age at birth.
Katie Abouzahr MD, vice president, autoantibody and maternal foetal immunology Disease Area Leader at J&J, commented: “Nipocalimab represents a novel approach for the treatment of patients at risk of severe HDFN who need proven, safe, non-surgical solutions to help address the serious health consequences of this condition. We are committed to addressing the substantial unmet need in this devastating disease.”
Betsy Goodfellow
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
